Literature DB >> 11093437

A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

L Sinigaglia1, A Nervetti, Q Mela, G Bianchi, A Del Puente, O Di Munno, B Frediani, F Cantatore, R Pellerito, S Bartolone, G La Montagna, S Adami.   

Abstract

OBJECTIVE: To determine the frequency of osteoporosis in a large cohort of women with rheumatoid arthritis (RA) and to investigate the main determinants of bone mineral density (BMD) and risk factors for vertebral fractures in this population.
METHODS: We recruited 925 consecutive female patients with RA at 21 Rheumatology Centers in Italy. For each patient pre-registered demographic, disease, and treatment-related variables were collected. BMD was measured at lumbar spine and proximal femur by dual x-ray absorptiometry technique. Collected variables underwent a univariate and multivariate statistical procedure. Osteoporosis was defined as BMD > -2.5 T score.
RESULTS: The frequency of osteoporosis in the whole sample was 28.8% at lumbar spine and 36.2% at femoral neck and increased linearly from Steinbrocker's functional stage I to IV (p = 0.0001). Patients with spinal or femoral osteoporosis were significantly older (p = 0.0001), had a lower body mass index (BMI) (p < 0.02), a significantly longer disease duration (p < 0.02) and a significantly higher Health Assessment Questionnaire (HAQ) score (p = 0.0001). These differences were significant, even after adjusting for age. Steroid use was associated with significantly lower lumbar and femoral BMD (p = 0.0001) even after adjusting for the main confounding covariates. Analysis of lateral spine radiographs revealed 74 women with at least one vertebral fracture. These women had a significantly lower lumbar and femoral BMD (p = 0.0001). The generalized linear model showed that steroid use, menopause, BMI, age, and HAQ were all significant independent predictors of lumbar and femoral BMD. The logistic procedure showed that age (OR 1.05, 95% CI 1.03-1.07), HAQ (OR 1.3, 95% CI 1.07-1.7), menopause (OR 1.9, 95% CI 1.1-3.2), use of steroids (OR 1.5, 95% CI 1.07-2.1), and BMI (OR 0.8, 95% CI 0.8-0.9) were significantly associated with the risk for osteoporosis. The only variables associated with an increased risk for vertebral fracture were age (OR 1.04, 95% CI 1.01-1.08), HAQ (OR 1.7, 95% CI 1.08-2.09), and cumulative steroid intake (OR for 1 g of prednisone 1.03, 95% CI 1.006-1.07).
CONCLUSION: To prevent osteoporosis and its dramatic complications in RA the therapeutic challenge is to preserve functional capacity using the lowest possible dosage of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093437

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  76 in total

Review 1.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

2.  Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.

Authors:  Seo Young Kim; Sebastian Schneeweiss; Jun Liu; Daniel H Solomon
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

Review 3.  Advances in the medical treatment of rheumatoid arthritis.

Authors:  J Michelle Kahlenberg; David A Fox
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

4.  [Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study)].

Authors:  I Heberlein; W Demary; H Bloching; J Braun; F Buttgereit; R Dreher; C Kuhn; U Lange; W Pollähne; A Zink; H Zeidler; H Häntzschel; H Raspe
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

Review 5.  [Systemic manifestations of rheumatoid arthritis].

Authors:  M Uffmann
Journal:  Radiologe       Date:  2006-05       Impact factor: 0.635

6.  [Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists].

Authors:  I Heberlein; W Demary; H Bloching; J Braun; F Buttgereit; R Dreher; C Kuhn; U Lange; A Zink; H Zeidler; H Häntzschel; H Raspe
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

Review 7.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

8.  Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.

Authors:  A Balasubramanian; S W Wade; R A Adler; C J F Lin; M Maricic; C D O'Malley; K Saag; J R Curtis
Journal:  Osteoporos Int       Date:  2016-06-08       Impact factor: 4.507

9.  The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis.

Authors:  Ratanapha Phuan-Udom; Nittaya Lektrakul; Wanruchada Katchamart
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

10.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.